Genomma Lab
Genomma Lab Internacional is a publicly-traded Mexican consumer healthcare company that develops, manufactures, and distributes 30+ branded OTC pharmaceuticals and personal care products across 19 Latin American countries and the United States through pharmacy, retail, and e-commerce channels.
- Company typePublic
- Founded1990
- HeadquartersVicente López, Argentina
- Headcount1,001–5,000
- GTM typeB2C
- OfferingHardware or Manufacturing
What Genomma Lab does
Genomma Lab Internacional, S.A.B. de C.V. is a Mexican publicly-listed consumer healthcare company (BMV: LABB) founded in 1990 and headquartered in Mexico City, operating across 19 countries in Latin America and the United States through wholly-owned local subsidiaries. The company develops, manufactures, and commercializes a portfolio of over 30 branded over-the-counter (OTC) pharmaceuticals, personal care, and beauty products organized by therapeutic category — including pain relief (Alliviax, Tafirol, Bengue), cold/flu (XL3, Next, Tukol-D), dermatology (Cicatricure, Asepxia, Goicoechea, Medicasp), hair care (Tío Nacho, Sistema GB), intimate health (Lomecan, Condones M), hydration (Suerox), foot care (Silka), and other categories such as Kaopectate, Nikzon, Novamil, and Groomen. Core technology centers on multi-disciplinary product safety infrastructure (farmacovigilancia, cosmetovigilancia, tecnovigilancia, nutrivigilancia) compliant with local regulations in each market, alongside Cofepris-certified manufacturing including a Toluca plant.
Genomma Lab generates revenue primarily through one-time sales of branded consumer health and personal care SKUs to mass-market consumers via a multi-channel distribution network. Distribution spans major pharmacy chains (Farmacias San Pablo, Raia Drogasil, Inkafarma, Fybeca), mass merchandisers (Walmart, Chedraui, Superama, Falabella, Jumbo), US retail (CVS, Walgreens, Target), and global e-commerce (Amazon, Mercado Libre, brand-owned storefronts). The company also pays dividends to public shareholders — most recently Mex$0.20 per share, representing a 5.3% trailing yield at a 36% payout ratio. Q1 2026 net sales were MXN 4,190.6 million (down 4.9% YoY) with EBITDA margin of 22.8%.
The company serves three primary segments: mass-market consumers in Latin America seeking accessible OTC and personal care products through pharmacy and retail channels; retail and pharmacy chains acting as distribution partners; and healthcare professionals engaged through the GEN Expertos pharmacist loyalty program. ESG credentials include MSCI ESG Rating (2024), Dow Jones Sustainability Index membership, and Cemafi ESR Distinction. Strategic priority areas disclosed include bolt-on brand M&A (four brands acquired July 2024 for US$25.6 million), debt refinancing for growth via MXN 1.2 billion in Cebures bonds issued June 2025, and packaging sustainability initiatives including carbon-neutral Tío Nacho packaging certified since 2022.
Genomma Lab firmographics
Firmographics- Name
- Genomma Lab
- Legal name
- Genomma Lab Internacional, S.A.B. de C.V.
- Website
- https://genommalab.com
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Genomma Lab Internacional is a publicly-traded Mexican consumer healthcare company that develops, manufactures, and distributes 30+ branded OTC pharmaceuticals and personal care products across 19 Latin American countries and the United States through pharmacy, retail, and e-commerce channels.
- Ownership category
- akta.pro rank
Genomma Lab industry classification
Industry- Product category
- Consumer Healthcare and OTC Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
- akta.pro secondary industries
- Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Feminine & Sexual Wellness OTC (Yeast Infection OTC, Lubricants, Condoms, Pregnancy Tests) (CRADAMAH)
Keywords
Where Genomma Lab is headquartered
LocationHeadquarters
- HQ city
- Vicente López
- HQ country
- Argentina
- HQ region
- Latin America
Offices18 records
Markets served
Genomma Lab business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D
Revenue model
- OTC Pharmaceuticals Sales: Sale of over-the-counter medications including pain relief, cold/flu, digestive health, and specialty categories through retail channels across Latin America.
- Personal Care Products: Hair care (Tío Nacho), skincare (Cicatricure, Asepxia, Goicoechea), foot care (Silka), and intimate health products sold through pharmacies, supermarkets, and direct-to-consumer e-commerce.
- Beauty Products: Cosmetic and beauty products including makeup, skincare treatments, and personal grooming products distributed through retail and beauty supply channels.
- Dividend Payments: The company pays dividends to shareholders, with Mex$0.20 per share dividend announced in 2026, representing a trailing yield of 5.3% and 36% payout ratio.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels6 records
Genomma Lab product offering
Product offeringCore offering
Genomma Lab develops, manufactures, and commercializes a diversified portfolio of over-the-counter (OTC) pharmaceuticals, personal care, and beauty products under 30+ owned brands across 19 countries in Latin America and the United States. The company's offering spans therapeutic categories including pain relief, cold/flu, skin care, hair care, intimate health, foot care, digestive health, and dermatology, distributed through pharmacy chains, supermarkets, and e-commerce channels.
Product overview
Genomma Lab is a consumer healthcare company offering a diversified portfolio of over-the-counter (OTC) pharmaceuticals, personal care, and beauty products across Latin America and the US. The company operates under a multi-brand strategy with iconic brands organized by therapeutic category: pain relief (Alliviax, Tafirol), cold/flu (XL3, Next, Tukol-D), skin care (Cicatricure, Teatrical, Asepxia, Goicoechea, DiabetTx), hair care (Tío Nacho with sustainability focus), intimate health (Lomecan, Condones M), foot care (Silka), digestive health (QG5, Kaopectate), and specialty categories (Nikzon, Novamil, Bio-electro, Sistema GB, Bengue, Xray, Unesia, Pointts, Shot-B, Sleepy, Groomen). Products are available across mass-market retail, pharmacies, and e-commerce channels in 18+ Latin American countries and the US.
Differentiator
Problem solved
Functional benefit
Brands
- Tío Nacho: Hair care products with over 100 years of experience; features sustainable packaging initiatives including 100% recycled PET bottles, FSC-certified cartons, and carbon-neutral packaging since 2022
- Suerox
- Alliviax
- Cicatricure
- XL-3
- Nikzon
- Lomecan
- Novamil
- Asepxia
- Teatrical
- Medicasp
- Next
- Tukol-D
- QG5
- Goicoechea
- Bengue
- Shot-B
- Xray
- Unesia
- Diabettx
- Pointts
- Groomen
- Kaopectate
- Tafirol
- Sleepy
- Condones M
- Silka
- Sistema GB
Products and services
- Suerox Hydration products for oral rehydration solutions for mass-market consumers.
- Alliviax Pain relief medications for headaches and general aches for mass-market consumers.
- Cicatricure Skin care products for scar treatment and skin healing for mass-market consumers.
- XL3 Cold and flu medications for respiratory symptom relief for mass-market consumers.
- Tío Nacho Hair care products including shampoos, conditioners, and treatments for hair strengthening and growth; available in 18+ Latin American countries with over 100 years of heritage and sustainability-focused packaging.
- Nikzon Hemorrhoid treatment products for mass-market consumers.
- Lomecan Intimate health products for mass-market consumers.
- Novamil Products for nursing mothers and infants for mass-market consumers.
- Bio-electro Migraine treatment products for mass-market consumers.
- Silka Foot care products for foot health and hygiene for mass-market consumers.
- Sistema GB Hair loss treatment and prevention products for mass-market consumers.
- Asepxia Acne and skin blemish treatment products for mass-market consumers.
- Teatrical Skin care and makeup products for mass-market consumers.
- Medicasp Dandruff treatment products for mass-market consumers.
- Next Cold and flu relief products for mass-market consumers.
- Tukol-D Cough relief medications for mass-market consumers.
- QG5 Colitis treatment products for mass-market consumers.
- Goicoechea Dermatological skin care products for mass-market consumers.
- Bengue Back pain relief products for mass-market consumers.
- Shot-B Performance enhancement supplements for mass-market consumers.
- Xray Joint health and arthritis relief products for mass-market consumers.
- Unesia Antifungal nail treatment products for onychomycosis for mass-market consumers.
- Diabettx Skin care products specifically designed for people with diabetes.
- Pointts Wart treatment products for mass-market consumers.
- Groomen Men's shaving and grooming products for mass-market consumers.
- Kaopectate Diarrhea relief medication for mass-market consumers.
- Tafirol Pain relief medications for mass-market consumers, primarily distributed in South American markets.
- Sleepy Sleep aid and relaxation products for mass-market consumers.
- Condones M Sexual health products including condoms for mass-market consumers.
- Tío Nacho Shampoo Collection Hair care product line including shampoos, conditioners, sprays, and treatments for various hair needs including anti-hair loss, thickening, hydration, and damage repair, available in multiple sizes and formulations.
- Tío Nacho Sustainability Line Sustainable hair care line featuring 100% recycled PET bottles, PP PCR caps, FSC-certified paper packaging, and carbon-neutral packaging since 2022.
Quantifiable outcome
- 100% carbon neutral packaging for Tío Nacho brand since 2022
- +3 more outcomes
Companies that use Genomma Lab
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
Genomma Lab technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Genomma Lab partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Ríos Limpios A.C.minorEnvironmental organization partner for the GEN Contigo volunteer program, collaborating on Xochimilco canal cleanup and conservation activities in Mexico City.
- UBEEScoreTío Nacho brand established Tío Nacho Bee Lab partnership with UBEES to protect over 1 million bees and pollinate more than 300 hectares in Antioquia, Colombia. The alliance includes regenerative beekeeping training and community empowerment programs for local farmers.
- Braskem IdesacorePartnership for incorporating recycled plastic developed by Braskem Idesa into packaging for multiple Genomma Lab brand products, supporting the company's sustainability objectives.
- Las Rosas Foundation (Chile)minorChilean foundation receiving donations of XL-3 alcohol gel products during COVID-19 pandemic as part of the GEN Contigo virtual volunteering initiative.
- Aquí Somos Todos Program - Canal 13 (Chile)minorTelevision program partnership in Chile for distributing alcohol gel donations to elderly communities during the COVID-19 pandemic.
- GENNEIAminorArgentine wind energy company providing carbon offset certificates that enabled Tío Nacho to achieve carbon neutrality for its packaging since 2022.
- EcoplasminorProfessional organization specialized in plastics and environment that certified Tío Nacho's recyclable packaging, identifying materials as recyclable.
- Forest Stewardship Council (FSC)minorGlobal nonprofit organization promoting responsible forest management. FSC certified Tío Nacho's paperboard packaging, ensuring materials come from responsibly managed forests.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
Genomma Lab competitors and assessment
Company assessmentBroad incumbents
- Haleon: Global consumer healthcare company spun off from GSK, with leading OTC brands (Panadol, Advil, Centrum, Sensodyne) distributed worldwide including LATAM. Comparable to Genomma in OTC category breadth and pharmacy retail presence, but at significantly larger scale with broader international footprint.
- Procter & Gamble: Global consumer packaged goods company with leading personal care, beauty, and grooming brands (Head & Shoulders, Gillette, Olay) sold through mass-market retail including in Latin America. Comparable to Genomma in personal care and beauty categories, mass-market retail reach, and brand-led marketing approach.
- Sanofi Consumer Healthcare: Global pharmaceutical company with significant consumer healthcare (OTC and personal care) business across LATAM, with brands like Dulcolax and Allegra. Overlaps with Genomma in OTC categories including digestive, pain, and cold/flu, sold through major LATAM pharmacy chains.
- Bayer Consumer Health: Global consumer health division of Bayer, with iconic OTC brands (Aspirin, Claritin, Aleve) sold through pharmacies and retailers globally including Latin America. Direct overlap with Genomma's OTC analgesics and cold/flu categories; competes with Genomma's Alliviax, XL3 and Next brands across LATAM markets.
- Kenvue: Consumer health company spun off from Johnson & Johnson, with leading OTC and personal care brands (Tylenol, Neutrogena, Aveeno, Zyrtec). Comparable to Genomma in OTC and personal care categories, retail pharmacy distribution, and brand-led consumer healthcare model, though with much larger global scale.
Direct peers
- Hypera Pharma: Brazil's largest OTC pharmaceutical and consumer-health company with a diversified brand portfolio across analgesics, cold/flu, dermatology, and personal care sold through pharmacy chains. Direct LATAM OTC peer to Genomma with overlapping categories and similar mass-market pharmacy distribution model.
- Eurofarma Laboratórios: Brazilian pharmaceutical company with branded generics, OTC, and consumer health portfolio distributed across Latin America. Comparable to Genomma in OTC breadth, pharmacy-channel focus, and regional commercial reach in markets including Brazil, Argentina, Mexico and the Andean region.
- Roemmers: Argentine pharmaceutical laboratory with a portfolio of branded prescription, OTC, and personal-care brands distributed across the Southern Cone and broader LATAM. Comparable to Genomma in OTC/pharmacy-led model, multi-country LATAM operations, and brand-led marketing approach.
- Laboratorios Bagó: Argentine pharmaceutical group with strong LATAM presence across branded generics, OTC, and personal care, distributed through pharmacy chains across Latin America. Direct competitor in core OTC categories (analgesics, cold/flu, dermatology) overlapping with Genomma's brand portfolio in Argentina and regional markets.
- Perrigo Company: US-headquartered OTC pharmaceutical and consumer self-care company focused on store-brand and value OTC products across analgesics, cold/flu, and skin care. Comparable to Genomma in OTC category leadership, mass-market distribution, and emphasis on affordable consumer healthcare products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Genomma Lab social profiles
Digital presenceGenomma Lab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genomma Lab leadership team
Management profileNumber of profiles
Profiles5 records
Genomma Lab subsidiaries and ownership
Company hierarchySubsidiaries17 records
Genomma Lab funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genomma Lab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genomma Lab
What does Genomma Lab do?
Genomma Lab develops, manufactures, and commercializes a diversified portfolio of over-the-counter (OTC) pharmaceuticals, personal care, and beauty products under 30+ owned brands across 19 countries in Latin America and the United States. The company's offering spans therapeutic categories including pain relief, cold/flu, skin care, hair care, intimate health, foot care, digestive health, and dermatology, distributed through pharmacy chains, supermarkets, and e-commerce channels.
Is Genomma Lab a public or private company?
Genomma Lab is a public company. It is classified as public and is currently operating.
When was Genomma Lab founded?
Genomma Lab was founded in 1990. It employs 1,001 to 5,000 people.
Where is Genomma Lab based?
Genomma Lab is headquartered in Vicente López, Argentina, in the Latin America region.
How does Genomma Lab make money?
Four revenue lines are on record. OTC Pharmaceuticals Sales are the primary driver. The others are personal Care Products, beauty Products and dividend Payments.
Who are Genomma Lab's main competitors?
Broad incumbents on record are Haleon, Procter & Gamble, Sanofi Consumer Healthcare, Bayer Consumer Health and Kenvue. Direct peers are Hypera Pharma, Eurofarma Laboratórios, Roemmers, Laboratorios Bagó and Perrigo Company.
Does Genomma Lab have an API?
No public API is recorded for Genomma Lab.
What industry is Genomma Lab in?
Genomma Lab's product category is Consumer Healthcare and OTC Pharmaceuticals. Its primary akta.pro industry code is CRABAAAF, Dermocosmetics & Medical-Grade Skincare, with a secondary code of CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges). Its NAICS code is 325412 and its SIC code is 2834.